ATGE Earnings

ATGE reported its earnings on 2026-01-28, showcasing a revenue of 503.38M against an estimate of 492.68M, resulting in a 2.17% surprise. The EPS was 2.43, surpassing the expected 2.19 by 10.96% . The stock experienced a -7.02% price change on the earnings day and a -14.24% change over the next five days, reflecting market reactions to the results.

Following ATGE's earnings announcement on 2026-01-28, the stock price moved by -7.02% on the day of the release. Over the subsequent five days, it saw a -14.24% change. Historically, ATGE's stock price tends to shift by an average of +0.54% in the 10 days leading up to earnings and +5.44% in the 10 days following, providing insight into potential market.

For 2026/Q3, analysts estimate ATGE’s annual revenue to reach 488.96M, while the EPS is projected at 2.06. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ATGE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ATGE's stock price typically moves by +0.54% in the 10 days before its earnings and +5.44% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 2.06 and revenue of 488.96M.

The earnings call highlights strong financial performance with a 12% revenue increase and a 34.3% rise in EPS. Despite increased investments impacting margins, strategic growth initiatives and robust enrollment in key segments like Walden and Medical/Veterinary are promising. Share repurchase plans and optimistic guidance further boost sentiment. Although some uncertainties exist, such as regulatory risks and vague partnership timelines, the overall outlook remains positive, particularly given the company's market cap and recent financial achievements.